Bexxar for non-Hodgkin's lymphoma

Canadian Coordinating Office for Health Technology Assessment
Record ID 32005001211
English, French
Authors' objectives:

The aim of this study was to review the available information on the use of tositumomab and iodine I 131 tositumomab (Bexxar, manufactured by Corixa Corporation; marketed by GlaxoSmithKline); indicated in the US for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), including patients with rituximab-refractory NHL.

Authors' results and conclusions: Trials have been conducted in three populations: treatment-naive NHL patients (FDA has not approved the use of Bexxar in these patients); patients previously treated with Bexxar (FDA has limited the treatment to one course); and previously treated NHL patients without previous exposure to Bexxar (the review of the evidence is limited to this population).
Authors' recommendations: Bexxar will be an option for patients who have failed standard treatments. The high acquisition cost, complex administration regimen, and daunting side-effect profile may be barriers to treatment initiation.
Authors' methods: Overview
Details
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2005
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, Non-Hodgkin
Contact
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.